![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PYGL |
Gene summary for PYGL |
![]() |
Gene information | Species | Human | Gene symbol | PYGL | Gene ID | 5836 |
Gene name | glycogen phosphorylase L | |
Gene Alias | GSD6 | |
Cytomap | 14q22.1 | |
Gene Type | protein-coding | GO ID | GO:0000272 | UniProtAcc | P06737 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5836 | PYGL | CA_HPV_2 | Human | Cervix | CC | 9.61e-06 | 2.43e-01 | 0.0391 |
5836 | PYGL | CCI_2 | Human | Cervix | CC | 7.27e-04 | 7.29e-01 | 0.5249 |
5836 | PYGL | Tumor | Human | Cervix | CC | 9.61e-43 | 8.14e-01 | 0.1241 |
5836 | PYGL | sample3 | Human | Cervix | CC | 1.37e-56 | 9.35e-01 | 0.1387 |
5836 | PYGL | T3 | Human | Cervix | CC | 1.22e-59 | 9.25e-01 | 0.1389 |
5836 | PYGL | LZE4T | Human | Esophagus | ESCC | 6.43e-19 | 6.22e-01 | 0.0811 |
5836 | PYGL | LZE7T | Human | Esophagus | ESCC | 2.76e-04 | 3.18e-01 | 0.0667 |
5836 | PYGL | LZE20T | Human | Esophagus | ESCC | 1.42e-07 | 3.89e-01 | 0.0662 |
5836 | PYGL | P4T-E | Human | Esophagus | ESCC | 2.45e-12 | 8.13e-02 | 0.1323 |
5836 | PYGL | P5T-E | Human | Esophagus | ESCC | 5.14e-24 | 5.90e-01 | 0.1327 |
5836 | PYGL | P8T-E | Human | Esophagus | ESCC | 1.19e-06 | 2.04e-02 | 0.0889 |
5836 | PYGL | P9T-E | Human | Esophagus | ESCC | 8.70e-15 | 3.24e-01 | 0.1131 |
5836 | PYGL | P10T-E | Human | Esophagus | ESCC | 1.46e-13 | 4.30e-01 | 0.116 |
5836 | PYGL | P11T-E | Human | Esophagus | ESCC | 3.16e-13 | 6.89e-01 | 0.1426 |
5836 | PYGL | P12T-E | Human | Esophagus | ESCC | 2.39e-02 | 2.05e-01 | 0.1122 |
5836 | PYGL | P15T-E | Human | Esophagus | ESCC | 2.00e-22 | 6.32e-01 | 0.1149 |
5836 | PYGL | P16T-E | Human | Esophagus | ESCC | 6.16e-17 | 3.39e-01 | 0.1153 |
5836 | PYGL | P17T-E | Human | Esophagus | ESCC | 1.03e-04 | 3.94e-01 | 0.1278 |
5836 | PYGL | P19T-E | Human | Esophagus | ESCC | 9.00e-08 | 1.43e+00 | 0.1662 |
5836 | PYGL | P20T-E | Human | Esophagus | ESCC | 6.88e-11 | 3.40e-01 | 0.1124 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:00159809 | Cervix | CC | energy derivation by oxidation of organic compounds | 74/2311 | 318/18723 | 3.83e-08 | 2.53e-06 | 74 |
GO:00196939 | Cervix | CC | ribose phosphate metabolic process | 72/2311 | 396/18723 | 4.49e-04 | 4.48e-03 | 72 |
GO:00425939 | Cervix | CC | glucose homeostasis | 50/2311 | 258/18723 | 7.57e-04 | 6.76e-03 | 50 |
GO:00335009 | Cervix | CC | carbohydrate homeostasis | 50/2311 | 259/18723 | 8.28e-04 | 7.22e-03 | 50 |
GO:00463908 | Cervix | CC | ribose phosphate biosynthetic process | 39/2311 | 190/18723 | 9.02e-04 | 7.77e-03 | 39 |
GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
GO:0015980110 | Esophagus | ESCC | energy derivation by oxidation of organic compounds | 220/8552 | 318/18723 | 1.20e-17 | 1.09e-15 | 220 |
GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
GO:0046390110 | Esophagus | ESCC | ribose phosphate biosynthetic process | 119/8552 | 190/18723 | 1.73e-06 | 2.06e-05 | 119 |
GO:00442626 | Esophagus | ESCC | cellular carbohydrate metabolic process | 160/8552 | 283/18723 | 1.43e-04 | 9.66e-04 | 160 |
GO:001605216 | Esophagus | ESCC | carbohydrate catabolic process | 91/8552 | 154/18723 | 5.39e-04 | 2.97e-03 | 91 |
GO:00973002 | Esophagus | ESCC | programmed necrotic cell death | 32/8552 | 47/18723 | 1.59e-03 | 7.43e-03 | 32 |
GO:00442751 | Esophagus | ESCC | cellular carbohydrate catabolic process | 27/8552 | 40/18723 | 4.39e-03 | 1.73e-02 | 27 |
GO:00702654 | Esophagus | ESCC | necrotic cell death | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
GO:001598022 | Liver | HCC | energy derivation by oxidation of organic compounds | 221/7958 | 318/18723 | 1.02e-22 | 1.86e-20 | 221 |
GO:001969322 | Liver | HCC | ribose phosphate metabolic process | 248/7958 | 396/18723 | 3.15e-16 | 2.70e-14 | 248 |
GO:001605222 | Liver | HCC | carbohydrate catabolic process | 99/7958 | 154/18723 | 3.79e-08 | 8.30e-07 | 99 |
GO:004639012 | Liver | HCC | ribose phosphate biosynthetic process | 116/7958 | 190/18723 | 1.79e-07 | 3.29e-06 | 116 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0492214 | Esophagus | ESCC | Glucagon signaling pathway | 64/4205 | 107/8465 | 2.18e-02 | 4.80e-02 | 2.46e-02 | 64 |
hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0493113 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0492215 | Esophagus | ESCC | Glucagon signaling pathway | 64/4205 | 107/8465 | 2.18e-02 | 4.80e-02 | 2.46e-02 | 64 |
hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0493121 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa0492241 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
hsa0491051 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0493131 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa0492251 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
hsa049108 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa049317 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa0491013 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa0493112 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PYGL | SNV | Missense_Mutation | c.1471C>A | p.Arg491Ser | p.R491S | P06737 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CR-7402-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD | |
PYGL | SNV | Missense_Mutation | novel | c.961N>A | p.Arg321Ser | p.R321S | P06737 | protein_coding | tolerated(0.24) | benign(0) | TCGA-CV-7104-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PYGL | SNV | Missense_Mutation | rs376771385 | c.79G>C | p.Glu27Gln | p.E27Q | P06737 | protein_coding | tolerated(0.29) | benign(0.24) | TCGA-CV-A45W-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PYGL | SNV | Missense_Mutation | c.682N>T | p.Asp228Tyr | p.D228Y | P06737 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CV-A461-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PYGL | SNV | Missense_Mutation | novel | c.1420N>A | p.Glu474Lys | p.E474K | P06737 | protein_coding | tolerated(0.15) | possibly_damaging(0.706) | TCGA-IQ-A61E-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
PYGL | SNV | Missense_Mutation | novel | c.1297N>A | p.Glu433Lys | p.E433K | P06737 | protein_coding | deleterious(0.03) | possibly_damaging(0.684) | TCGA-IQ-A61E-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
PYGL | SNV | Missense_Mutation | rs760187622 | c.2426N>T | p.Ser809Leu | p.S809L | P06737 | protein_coding | tolerated(0.08) | possibly_damaging(0.734) | TCGA-KK-A6E3-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
PYGL | SNV | Missense_Mutation | rs760187622 | c.2426N>T | p.Ser809Leu | p.S809L | P06737 | protein_coding | tolerated(0.08) | possibly_damaging(0.734) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
PYGL | SNV | Missense_Mutation | c.2254T>C | p.Ser752Pro | p.S752P | P06737 | protein_coding | deleterious(0) | benign(0.205) | TCGA-BR-4201-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
PYGL | SNV | Missense_Mutation | c.727N>T | p.Arg243Cys | p.R243C | P06737 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5836 | PYGL | DRUGGABLE GENOME, ENZYME | dexamethasone | DEXAMETHASONE | 23007406 | |
5836 | PYGL | DRUGGABLE GENOME, ENZYME | methotrexate | METHOTREXATE | 23007406 | |
5836 | PYGL | DRUGGABLE GENOME, ENZYME | PSN357 | |||
5836 | PYGL | DRUGGABLE GENOME, ENZYME | asparaginase | ASPARAGINASE | 23007406 |
Page: 1 |